ストックスクリーナーアプリを入手
3.20
0.88%
-0.0285
アフターアワーズ：
3.20
前日終値:
$3.2285
開ける：
$3.27
24時間の取引高:
722
Relative Volume:
0.10
時価総額：
$10.19M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.19%
1か月 パフォーマンス:
-13.51%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.0215
$3.27
1週間の範囲:
$2.8104
$3.3962
52週間の値動き範囲:
$2.8104
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
CSCI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CSCI | 3.20 | 10.19M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cosciens Biopharma Inc (CSCI) 最新ニュース
Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance
COSCIENS Biopharma: Q3 Earnings Snapshot - Houston Chronicle
COSCIENS Biopharma Advances Merger and Pipeline - TipRanks
Shimmick Announces New CEO - The Manila Times
COSCIENS Biopharma Inc. Reports Third Quarter 2024 - GlobeNewswire
COSCIENS Q3 Loss Widens to $5.8M, Discontinues Key Programs Amid Pipeline Shift | CSCI Stock News - StockTitan
CSCI stock touches 52-week low at $3.4 amid market fluctuations - Investing.com India
Hypoparathyroidism Market to Grow by USD 474.9 Million from 2024-2028, Driven by Thyroid Treatment Awareness Programs and AI-Powered Market InsightsTechnavio - PR Newswire
Cosciens Biopharma (TSX:CSCI) EPS without NRI : C$-4.32 (TTM As of Jun. 2024) - GuruFocus.com
AEterna Zentaris : March 10, 2015 Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015 - Marketscreener.com
Yorvipath-finders? Septerna, others forge on in hypothyroidism - BioWorld Online
Cosciens Biopharma (FRA:ET8) Enterprise Value : €-13.18 Mil (As of Oct. 17, 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Cash From Discontinued Investi - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Profitability Rank : 5 (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Shares Outstanding (EOP) : 3.06 Mil (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Free Cash Flow : €-5.76 Mil (TTM As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Long-Term Debt & Capital Lease Obligation : €1.19 Mil (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Inventory-to-Revenue : 1.40 (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) 3-Year Revenue Growth Rate : -13.80% (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Cyclically Adjusted PS Ratio : 0.56 (As of Oct. 16, 2024) - GuruFocus.com
The Escalator: Syneos Health, The FDA, Pfizer and more - MM+M Online
COSCIENS Biopharma streamlines board with resignation By Investing.com - Investing.com Canada
COSCIENS Biopharma reshuffles board of directors By Investing.com - Investing.com South Africa
COSCIENS Biopharma streamlines board with resignation - Investing.com
COSCIENS Biopharma reshuffles board of directors - Investing.com India
Cosciens Biopharma director Carolyn Egbert resigns - TipRanks
COSCIENS Biopharma Restructures Board After Resignation - TipRanks
COSCIENS Biopharma Announces Change to Board of Directors - GlobeNewswire
AgEagle Aerial Systems Inc. Announces Closing of $6.5 Million Public Offering - The Manila Times
COSCIENS Biopharma names new board director By Investing.com - Investing.com South Africa
COSCIENS Biopharma names new board director - Investing.com
COSCIENS Biopharma Welcomes New Board Director - TipRanks
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director - The Manila Times
Cintas (NASDAQ:CTAS) Reaches New 12-Month High at $209.59 - MarketBeat
Cintas Stock Hits All-Time High Amid Strong Results, Outlook Lift - MSN
Cintas stock soars to all-time high, hits $209.13 - Investing.com India
Cintas rises on raising annual profit, revenue forecasts - XM
Cintas’s shares rise on improved earnings guidance (NASDAQ:CTAS) - Seeking Alpha
Cintas Beats Q1 Earnings On Margin Strength, Boosts Outlook - Yahoo Finance UK
Cintas earnings beat by $0.10, revenue topped estimates - Investing.com Australia
Cintas (NASDAQ:CTAS) Releases FY25 Earnings Guidance - Defense World
Cintas stock gains 2% on Q1 earnings beat, raises full-year outlook - Investing.com Australia
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Buys 6,562 Shares of Cintas Co. (NASDAQ:CTAS) - Defense World
Colombia defeats ICSID case over internet domain name - Latin Lawyer
Scalar Gauge Management LLC Decreases Stock Position in Cintas Co. (NASDAQ:CTAS) - Defense World
Why Carpenter Tech (CRS) Stock is Surging Despite Boeing's (BA) Troubles - GuruFocus.com
COSCIENS Biopharma announces management changes, integration progress - Investing.com
Toronto Stocks Flat; Bitfarms Up on Settlement with Riot Platforms - Marketscreener.com
Cosciens Biopharma Shares Fall on ALS Treatment Research End, Cost Cutting - MarketWatch
Cosciens Biopharma provides update on development projects - TipRanks
Cosciens Biopharma Inc (CSCI) 財務データ
Cosciens Biopharma Inc (CSCI) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):